文献速递中医内科中药与中成药合理使用

黄连提取物颗粒治疗2型糖尿病的有效剂量:医院回顾性队列研究

Effective Dose of Rhizoma Coptidis Extract Granules for Type 2 Diabetes Treatment: A Hospital-Based Retrospective Cohort Study.
PubMed 文献 · Front Pharmacol · 2021-01-25

该研究基于长庚研究数据库2008至2017年数据,纳入93例接受黄连提取物颗粒(RCEG)治疗的2型糖尿病门诊患者,共737次就诊。研究发现RCEG剂量达到0.08 g/kg/天或以上时与HbA1c降低显著相关,高剂量组总胆固醇显著下降,且未显示肾毒性或肝毒性。

要点

  • RCEG最低有效剂量为0.08 g/kg/天,高剂量组(≥0.08 g/kg/d)降HbA1c效果显著。
  • 高剂量RCEG组总胆固醇显著降低,甘油三酯呈下降趋势。
  • 初始HbA1c较高、心率较快、肝功能较好者对RCEG反应更佳。

核心结论

  • RCEG剂量超过0.08 g/kg/天对2型糖尿病患者血糖和血脂控制有益,且未显示肾毒性或肝毒性。

主要发现

  • RCEG剂量达到0.08 g/kg/天或以上时与HbA1c降低呈显著关系。
  • 高剂量RCEG组(≥0.08 g/kg/d)总胆固醇显著下降,甘油三酯呈下降趋势。
  • 初始HbA1c较高、心率较快、肝功能较好、对高剂量和疗程耐受性更好的患者对RCEG治疗反应更有效。

关键数值与推荐

  • RCEG最低有效剂量定义为0.08 g/kg/天,并作为高剂量组(≥0.08 g/kg/d)与低剂量组(<0.08 g/kg/d)的分界阈值。

临床怎么用

  • 临床使用RCEG治疗2型糖尿病时,可考虑剂量达到0.08 g/kg/天或以上以增强降糖和降脂效果,并关注患者初始HbA1c、心率、肝功能及耐受性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Rhizoma Coptidis is a popular phytomedicine for the treatment of type 2 diabetes in Asia, but its effective dose for diabetes treatment remains confused because of diverse origins. This study aimed to investigate the dose-response effects of Rhizoma Coptidis extract granules (RCEG), produced with standardized quality control, on hypoglycemic effects in patients with type 2 diabetes. We conducted a retrospective analysis of Chang Gung Research Database from January 01, 2008 to November 30, 2017. Outpatients visiting traditional Chinese medicine clinics and receiving RCEG for type 2 diabetes treatment were included. Plasma glucose, lipid, and other parameters were analyzed from 93 patients with a total of 737 visits within 60 weeks. Scatter plots with the LOESS analysis were used to explore the association between RCEG dose and hypoglycemic effect. The minimal effective dose was chosen to divide the study population into the high-dose and low-dose RCEG groups. Non-parametric tests were used for between-group and within-group comparisons. The multivariate nonlinear mixed-effects model was applied to access the effect of treatment length and groups simultaneously on the change of HbA1c and fasting plasma glucose. The "arule" package in R was used to present the network diagram of RCEG and other co-prescriptions. We first discovered a significant relationship between RCEG dose and HbA1c reduction when the dose reached 0.08 g/kg/day or higher. We thus defined 0.08 g/kg/day of RCEG as the minimum effective dose, and a threshold to separate patients into the high-dose (≥0.08 g/kg/d) and low-dose (<0.08 g/kg/d) RCEG groups. In the high-dose RCEG group, a significant decrease in total cholesterol and a trend toward triglyceride reduction were also noted. Patients more effectively responded to RCEG treatment if they had a higher initial HbA1c level, higher heart rates, better liver function tests, and better tolerance to the higher dose and treatment duration of RCEG. In addition, digestive/tonic/dampness draining formulas and blood regulation recipes were two of the most frequent co-prescriptions with RCEG. This study concluded that RCEG at a dose exceeding 0.08 g/kg/d had beneficial effects on glycemic and lipid control, without showing nephro- or hepatotoxicity, in patients with type 2 diabetes.

来源:Front Pharmacol,查看原文。版权归原作者所有。

引用

  1. Huang YH, Liu GH, Hsu TY, et al. Effective Dose of Rhizoma Coptidis Extract Granules for Type 2 Diabetes Treatment: A Hospital-Based Retrospective Cohort Study. Front Pharmacol. 2021. PMID: 33568997. doi:10.3389/fphar.2020.597703

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。